Shattuck Labs Reports Q1 2026 Financials, Reaffirms Cash Runway into 2029, and Advances Clinical Pipeline

summarizeSummary

Shattuck Labs reported a Q1 2026 net loss of $14.8 million but reaffirmed its cash runway into 2029, while also announcing the completion of Phase 1 enrollment for SL-325 and plans for a Phase 2 trial.

check_boxKey Events

• Q1 2026 Financial Results

  Shattuck Labs reported a net loss of $14.8 million, or $0.13 per basic and diluted share, for the first quarter ended March 31, 2026, compared to a net loss of $13.7 million, or $0.27 per share, for the same period in 2025.

• Cash Runway Reaffirmed

  The company reported $90.4 million in cash and cash equivalents and investments as of March 31, 2026, and expects this to fund operations into 2029, assuming the full exercise of outstanding common stock warrants.

• SL-325 Clinical Trial Progress

  Enrollment for all cohorts in the Phase 1 clinical trial of SL-325 is complete, with data expected in the second quarter of 2026. Subject to positive Phase 1 data, a Phase 2 clinical trial in Crohn's disease is expected to initiate in the third quarter of 2026.

• Bispecific Antibody Development

  Shattuck's lead bispecific antibody has entered IND-enabling activities, with plans to disclose targets, preclinical data, and development timelines in the second quarter of 2026.

auto_awesomeAnalysis

Shattuck Labs, a clinical-stage biotechnology company, reported a widened net loss for Q1 2026, but significantly, reaffirmed its cash runway into 2029, providing crucial financial stability for its ongoing clinical programs. The completion of Phase 1 enrollment for its lead candidate, SL-325, and the planned initiation of a Phase 2 trial in Crohn's disease are key milestones. Additionally, the advancement of a lead bispecific antibody into IND-enabling activities signals continued pipeline development. These clinical advancements, coupled with a strong cash position, are critical for investor confidence in a biotech company.